The study of the asbestosis toxicity identifying; the potential of novel mineral treatment in the mouse. A proportion of idiopathic pulmonary fibrosis cases; may be linked with asbestos exposure. That current treatment strategies need to be altered as people with a history of asbestos exposure are not currently able to access new treatments for idiopathic pulmonary fibrosis.
Asbestos-related cancers include lung cancer and malignant mesothelioma for which there is no cure. But most patients with MM die within two years of diagnosis; and despite the banning of asbestos in many countries MM relating deaths are predicting to rise in both industrialised and developing countries. Research finding that the zeolite clinoptilolite reduced asbestos-induced cellular damage in cell lines and significantly reduced MM development in mouse models.
Asbestosis toxicity identification
Asbestosis is the name giving to the lung disease developing by people with a knowing history of exposure to asbestos. The symptoms and presentation of this disease can be identical to IPF; the only difference between the two diseases is whether a patient knows about their exposure to asbestos. People with asbestosis are not currently eligible for new treatments for idiopathic pulmonary fibrosis.
But clinoptilolite is a naturally occurring mineral; used for a variety of purposes including as an odour absorber and as both a food and feed additive. The mineral has GRAS status under the USFDA. The study analysing the mortality rates for IPF, asbestosis and mesothelioma across England and Wales. Research tested the theory that the metal-binding properties of zeolites would trap iron molecules released from asbestos fibres and thus reduce asbestosis toxicity.
The analysis revealing national and regional correlations between the three diseases, which supports the theory that a proportion of IPF cases are due to unknown exposure to asbestos. If this asbestos exposure was knowing, it would be likely that these patients were diagnosed with asbestosis. This is the first report of success in delaying or preventing MM in an animal model. But more research is needing in this area; particularly as patients knowing to have asbestos exposure are not currently considering to be candidates for new treatments for IPF; and this may be inappropriate.
The scientists say that new treatments for MM; and asbestosis have been slow to progress and is a factor in underlining the potential of the current study. The study is preliminary data only and the team recognises the difficulty in reproducing animal studies in humans. However, we expect that due to the incurable nature of malignant mesothelioma; we might be able to fast-track a Phase I trial.